Drug Trial Radar · NCT05354089
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Apr 27, 2022
Primary completion
Jul 9, 2022
Study completion Oct 1, 2023
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety, tolerability, immunogenicity and immune persistence of SYS6006 (SARS-CoV-2 mRNA Vaccine) in 18-59 year old healthy population.
Conditions
- SARS-CoV-2
Interventions
20 μg dose of SYS6006Biological
20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
30 μg dose of SYS6006Biological
30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
PlaceboDrug
Placebo IM on day 0 and day 21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events, including solicited and unsolicited eventsTime frame: From the first dose through 30 days following the second dose.
- adverse events associated with the study interventionTime frame: From the first dose through 30 days following the second dose.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sir Run Run Hosipital Nanjing Medical University
Nanjing, Jiangsu, China
Shulan(hangzhou) Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.